Privia Health Group (NASDAQ:PRVA) CFO David Mountcastle Sells 17,196 Shares of Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 17,196 shares of the stock in a transaction on Friday, June 26th. The stock was sold at an average price of $25.18, for a total value of $432,995.28. Following the completion of the transaction, the chief financial officer directly owned 211,462 shares of the company’s stock, valued at approximately $5,324,613.16. The trade was a 7.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Mountcastle also recently made the following trade(s):

• On Monday, May 11th, David Mountcastle sold 3,385 shares of Privia Health Group stock. The shares were sold at an average price of $22.60, for a total transaction of $76,501.00.
• On Monday, May 4th, David Mountcastle sold 1,206 shares of Privia Health Group stock. The shares were sold at an average price of $25.00, for a total transaction of $30,150.00.
• On Friday, May 1st, David Mountcastle sold 7,179 shares of Privia Health Group stock. The shares were sold at an average price of $25.03, for a total transaction of $179,690.37.
• On Thursday, April 2nd, David Mountcastle sold 5,566 shares of Privia Health Group stock. The stock was sold at an average price of $20.85, for a total transaction of $116,051.10.

Privia Health Group Price Performance

Privia Health Group stock opened at $25.73 on Wednesday. Privia Health Group, Inc. has a 12-month low of $18.77 and a 12-month high of $26.51. The stock has a market capitalization of $3.24 billion, a PE ratio of 160.82, a price-to-earnings-growth ratio of 2.02 and a beta of 0.90. The firm has a 50 day simple moving average of $23.25 and a 200-day simple moving average of $22.96.

Privia Health Group (NASDAQ:PRVA) last released its earnings results on Thursday, May 7th. The company reported $0.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.11. The firm had revenue of $603.85 million during the quarter, compared to the consensus estimate of $560.99 million. Privia Health Group had a return on equity of 2.81% and a net margin of 0.97%.The firm’s revenue for the quarter was up 25.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.22 earnings per share. On average, analysts forecast that Privia Health Group, Inc. will post 0.27 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on PRVA. Canaccord Genuity Group dropped their price target on shares of Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Weiss Ratings lowered shares of Privia Health Group from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. Citigroup lowered their price objective on shares of Privia Health Group from $34.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, March 3rd. Evercore set a $26.00 price objective on Privia Health Group in a research report on Wednesday, April 8th. Finally, Barclays reduced their price objective on Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 26th. Eleven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $31.15.

Institutional Investors Weigh In On Privia Health Group

Several hedge funds have recently made changes to their positions in the company. Royal Bank of Canada grew its position in Privia Health Group by 63.5% during the 1st quarter. Royal Bank of Canada now owns 245,633 shares of the company’s stock worth $5,514,000 after purchasing an additional 95,371 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Privia Health Group by 24.7% in the first quarter. AQR Capital Management LLC now owns 40,781 shares of the company’s stock worth $916,000 after buying an additional 8,068 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Privia Health Group by 3.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 118,764 shares of the company’s stock worth $2,666,000 after buying an additional 3,714 shares during the period. Intech Investment Management LLC grew its holdings in shares of Privia Health Group by 55.1% during the first quarter. Intech Investment Management LLC now owns 56,553 shares of the company’s stock valued at $1,270,000 after buying an additional 20,082 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new position in Privia Health Group during the first quarter valued at $154,000. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.